Search clinical trials for: Talazoparib

Total 116 results

National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
Seoul National University Hospital

Recruiting

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Advanced Breast Cancer

Korea, Republic of
Samsung Medical Center

Not yet recruiting

PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study (Young-PALETTA)

Premenopausal HR+/HER2- Metastatic Breast Cancer

Korea, Republic of
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
Pfizer

Completed

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Neoplasms

China
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
Brown University
Pfizer; Lifespan

Terminated

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian Cancer | Fallopian Tube Cancer | BRCA1 Mutation | BRCA2 Mutation | High Grade Serous Carcinoma

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
Stanford University
Pfizer

Recruiting

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Erasmus Medical Center
University Medical Center Groningen; Leiden University Medical Center

Recruiting

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE)

Advanced Breast Cancer

Netherlands
Centre Francois Baclesse
Pfizer

Recruiting

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (TALASUR)

Urothelial Carcinoma

France
Pfizer
Astellas Pharma Inc

Active, not recruiting

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

mCRPC

China, Finland, Spain, United States, Hungary, Israel, Belgium, Korea, Republic of, France, Canada, Czechia, Australia, Japan, Brazil, Germany, Argentina, New Zealand, United Kingdom, Norway, South Africa, Poland, Portugal, Chile, Italy, Pe... and more
University of Maryland, Baltimore
Pfizer; Van Andel Research Institute

Completed

Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC)

Acute Myeloid Leukemia

United States
University Health Network, Toronto
Pfizer

Recruiting

Talazoparib and Thoracic RT for ES-SCLC

Lung Cancer | Small-Cell Lung Cancer

Canada
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Pfizer
Astellas Pharma Inc

Active, not recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

United States, Finland, China, France, Spain, Hungary, United Kingdom, Korea, Republic of, Canada, Czechia, Taiwan, Belgium, Australia, Argentina, Japan, Germany, India, Turkey, Slovakia, Russian Federation, Bulgaria, Italy, Ukraine, ... and more
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
M.D. Anderson Cancer Center

Not yet recruiting

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Prostate Cancer

United States
German Cancer Research Center

Not yet recruiting

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia (NAKIP-AML)

Acute Myeloid Leukemia
University Hospital, Caen

Completed

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Cancer

France
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation
Strata Oncology
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences

Recruiting

Strata PATH™ (Precision Indications for Approved Therapies) (Strata PATH)

Cancer | Advanced Solid Tumor

United States
University Hospital, Caen

Completed

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Cancer

France
Pfizer
EMD Serono; Astellas Pharma Inc; Nektar Therapeutics

Terminated

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)

Spain, United States, Poland, Belgium
Melbourne Health
Sanofi; National Heart Foundation, Australia

Terminated

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Deep Vein Thrombosis

Australia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
University of Malaya
Pfizer; Cancer Research Malaysia; Pantai Hospital Kuala Lumpur; Hospital Sultan...

Recruiting

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Triple Negative Breast Cancer | HRD 100 Gene Expression High

Malaysia
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Metastatic Castration-Resistant Prostate Cancer
Khoo Teck Puat Hospital

Completed

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Diabetes

Singapore
Yonsei University

Not yet recruiting

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

Korea, Republic of
Haider Mahdi
Pfizer; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Massachusetts General Hospital
Pfizer

Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Breast Cancer

United States
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Breast Neoplasms | Metastatic Breast Cancer

United States
National University Hospital, Singapore

Recruiting

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Advanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast Cancers

Singapore
Pfizer

Completed

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Pfizer
Medivation, Inc.

Completed

Open-Label Extension and Safety Study of Talazoparib

Cancer

United States, Canada, United Kingdom, France, Poland, Hungary, Germany, Moldova, Republic of, Russian Federation
National Cancer Institute (NCI)

Completed

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Advanced Breast Cancer | Advanced Solid Tumors | Primary Peritoneal Cancer | Advanced Ovarian Cancer

United States
Pfizer

Completed

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Human Volunteers

United States
Pfizer
Medivation, Inc.

Completed

A Study of Talazoparib in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Hungary
Fox Chase Cancer Center

Not yet recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Pfizer

Not yet recruiting

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Breast Neoplasms
Hospices Civils de Lyon

Not yet recruiting

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)

Advanced Malignant Pleural or Peritoneal Mesothelioma
University College, London
Medivation, Inc.

Withdrawn

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer (PANDA)

Endometrial Cancer

United Kingdom
Pfizer
Medivation, Inc.

Completed

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Breast Neoplasms | Small Cell Lung Carcinoma | Prostate Cancer | Ewing Sarcoma | Pancreas Cancer | Ovarian Cancer, Epithelial | Advanced or Recurrent Solid Tumors

United States, United Kingdom
Pfizer
Medivation, Inc.

Completed

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Acute Myeloid Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome

United Kingdom, United States
MedSIR
Pfizer

Active, not recruiting

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (ZZ-First)

Metastatic Prostate Cancer

Spain

Search clinical trials for: Talazoparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations